Allena Pharmaceuticals assumed with a Buy at B. Riley FBR. B. Riley FBR analyst Mayank Mamtani assumed coverage of Allena Pharmaceuticals with a Buy rating and $22 price target. The analyst says that while the company’s Phase III Urirox-2 trial is slightly delayed, it remains on track to be a “de-risking” event.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.